Given the aggressive nature of MYCN-amplified NB, and the fact that NB relapses can be refractory to treatment, these data are an important first step in rationalizing the further study of ISLQ as a potential therapeutic agent for high-risk pediatric NB. The gene discussed is MYCN; the disease is neuroblastoma.